243 related articles for article (PubMed ID: 12207774)
1. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
Esfandiarpour I; Alavi A
Int J Dermatol; 2002 Aug; 41(8):521-4. PubMed ID: 12207774
[TBL] [Abstract][Full Text] [Related]
2. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study.
Esfandiarpour I; Dabiri SH
Int J Dermatol; 2007 Aug; 46(8):848-52. PubMed ID: 17651170
[TBL] [Abstract][Full Text] [Related]
3. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
[TBL] [Abstract][Full Text] [Related]
4. Allopurinol in the treatment of American cutaneous leishmaniasis.
Martinez S; Marr JJ
N Engl J Med; 1992 Mar; 326(11):741-4. PubMed ID: 1738379
[TBL] [Abstract][Full Text] [Related]
5. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial.
Velez I; Agudelo S; Hendrickx E; Puerta J; Grogl M; Modabber F; Berman J
Ann Intern Med; 1997 Feb; 126(3):232-6. PubMed ID: 9027276
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Cutaneous Leishmaniasis with Allopurinol Plus Itraconazole in Iran.
Mashayekhi Goyonlo V; Derakhshan Z; Darchini-Maragheh E
Am J Trop Med Hyg; 2023 Jun; 108(6):1164-1166. PubMed ID: 37094789
[TBL] [Abstract][Full Text] [Related]
7. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate.
Momeni AZ; Reiszadae MR; Aminjavaheri M
Int J Dermatol; 2002 Jul; 41(7):441-3. PubMed ID: 12121563
[TBL] [Abstract][Full Text] [Related]
8. Both combined oral azithromycin plus allopurinol and intramuscular Glucantime yield low efficacy in the treatment of Old World cutaneous leishmaniasis: a randomized controlled clinical trial.
Dastgheib L; Naseri M; Mirashe Z
Int J Dermatol; 2012 Dec; 51(12):1508-11. PubMed ID: 23171020
[TBL] [Abstract][Full Text] [Related]
9. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV.
Laguna F; López-Vélez R; Soriano V; Montilla P; Alvar J; González-Lahoz JM
J Infect; 1994 May; 28(3):255-9. PubMed ID: 8089514
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran.
Mohammadzadeh M; Behnaz F; Golshan Z
J Infect Public Health; 2013 Apr; 6(2):120-4. PubMed ID: 23537825
[TBL] [Abstract][Full Text] [Related]
11. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.
Pourmohammadi B; Motazedian MH; Handjani F; Hatam GH; Habibi S; Sarkari B
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):502-8. PubMed ID: 21706927
[TBL] [Abstract][Full Text] [Related]
12. Treatment of recurrent cutaneous Leishmaniasis.
Momeni AZ; Aminjavaheri M
Int J Dermatol; 1995 Feb; 34(2):129-33. PubMed ID: 7737774
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
Layegh P; Yazdanpanah MJ; Vosugh EM; Pezeshkpoor F; Shakeri MT; Moghiman T
Am J Trop Med Hyg; 2007 Jul; 77(1):99-101. PubMed ID: 17620637
[TBL] [Abstract][Full Text] [Related]
14. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis.
Sadeghian G; Nilforoushzadeh MA
Int J Dermatol; 2006 Jul; 45(7):819-21. PubMed ID: 16863518
[TBL] [Abstract][Full Text] [Related]
15. Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy.
Shamsi Meymandi S; Javadi A; Dabiri S; Shamsi Meymandi M; Nadji M
Arch Iran Med; 2011 Jul; 14(4):238-43. PubMed ID: 21726098
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.
Asilian A; Sadeghinia A; Faghihi G; Momeni A
Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013
[TBL] [Abstract][Full Text] [Related]
17. Chronic zosteriform cutaneous leishmaniasis.
Omidian M; Mapar MA
Indian J Dermatol Venereol Leprol; 2006; 72(1):41-2. PubMed ID: 16481709
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate.
Sadeghian G; Nilfroushzadeh MA; Iraji F
Clin Exp Dermatol; 2007 Jul; 32(4):371-4. PubMed ID: 17376205
[TBL] [Abstract][Full Text] [Related]
19. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis.
Arevalo I; Tulliano G; Quispe A; Spaeth G; Matlashewski G; Llanos-Cuentas A; Pollack H
Clin Infect Dis; 2007 Jun; 44(12):1549-54. PubMed ID: 17516397
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of lupoid cutaneous leishmaniasis with glucantime and topical trichloroacetic acid (a case report).
Nilforoushzadeh MA; Sadeghian G; Jaffary F; Ziaei H; Shirani-Bidabad L; Mahzoni P
Korean J Parasitol; 2008 Sep; 46(3):175-7. PubMed ID: 18830058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
